TABLE 2

Hyperglycemic clamp results in subjects with NGT and IGT according to KIR6.2 E23K genotype

NGT
IGT
E/EE/KK/KE/EE/KK/K
n (M/F)26 (10/16)32 (4/28)7 (1/7)34 (14/20)50 (26/24)10 (5/5)
First-phase insulin secretion (pmol/l)1,707 (1,200–2,783)1,659 (1,101–2,181)1,698 (774–2,550)600 (200–1,084)593 (290–1,035)370 (161–1,556)
Second-phase insulin secretion (pmol/l)325 (248–473)286 (211–390)302 (262–522)314 (169–428)199 (131–347)235 (132–382)
Glucose metabolized (mg · kg−1 · min−1)10.5 (7.9–13.0)8.8 (6.4–10.5)8.1 (7.4–13.4)5.6 (3.5–7.1)4.9 (4.0–6.2)5.7 (5.0–7.9)
Insulin sensitivity index 100 × (mg · kg−1 · min−1/pmol/l)2.9 (1.8–5.1)3.1 (2.3–4.0)2.0 (1.4–5.1)1.6 (1.0–2.8)2.2 (1.4–3.0)2.3 (1.3–4.8)
DI (mg · kg−1 · min−1)54.0 (33.5–73.0)52.8 (36.0–66.1)33.3 (18.6–56.5)8.9 (3.9–16.4)11.6 (6.8–22.4)23.5 (3.1–40.5)
  • Data are means ± SE or median (interquartile range). E, glutamic acid; K, lysine. Differences between the genotypes were tested by ANOVA, P > 0.1 for all comparisons with or without correction for age, sex, and BMI.